Drugs / Gebasaxturev
Gebasaxturev
also known as
CVA21 · Coxsackievirus A21 · CAVATAK · V937 · Formerly known as CAVATAK · Human coxsackievirus a21
Other / unclassified targets ICAM1 via depletion
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT03408587 | Jan 2018 → May 2019 | uveal melanoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT02824965 | Aug 2017 → Jul 2021 | non-small cell lung carcinoma | Olivia Newton-John Cancer Research Institute | Unknown | No outcome recorded |
| Phase 1 | NCT02565992 | Dec 2015 → Nov 2019 | melanoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT02307149 | May 2015 → Nov 2019 | melanoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT02316171 | Jan 2015 → Mar 2016 | non-invasive bladder urothelial carcinoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT02043665 | Dec 2013 → Jan 2020 | non-small cell lung carcinoma, urinary bladder cancer | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT00832559 | Jan 2009 → Jul 2011 | head and neck cancer | Viralytics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00636558 | Feb 2008 → Jan 2012 | breast cancer, melanoma, prostate cancer | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT00438009 | May 2007 → Aug 2009 | melanoma | Viralytics | Completed | No outcome recorded |
| Phase 1 | NCT00235482 | Nov 2005 → Apr 2006 | melanoma | Viralytics | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04521621 | Oct 2020 → Jul 2023 | metastatic neoplasm | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04303169 | Jun 2020 → Sep 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT04152863 | Jun 2020 → Jul 2023 | metastatic melanoma | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT01636882 | Jul 2012 → Apr 2016 | melanoma | Viralytics | Completed | No outcome recorded |
| Phase 2 | NCT01227551 | Dec 2011 → Apr 2016 | melanoma | Viralytics | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gebasaxturev | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04152863 ↗ |
| Known as | CAVATAK | “CAVATAK™ (Coxsackievirus A21, CVA21)” NCT01636882 ↗ |
| Known as | Coxsackievirus A21 | “Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in...” PMID 36669791 ↗ Jan 2023 |
| Known as | CVA21 | “CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.” NCT01227551 ↗8“Coxsackievirus A21 (CVA21) is a naturally occurring virus” NCT00438009 ↗ |
| Known as | Formerly known as CAVATAK | “Formerly known as CAVATAK®” NCT04303169 ↗ |
| Known as | Human coxsackievirus a21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095439 ↗ |
| Known as | V937 | “Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in...” PMID 36669791 ↗ Jan 20232“CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB-IV melanoma.” PMID 36445410 ↗ Nov 2022 “Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.” PMID 34464163 ↗ Aug 2021 |
| Action | Deplete | “it can infect and lyse melanoma” NCT00235482 ↗ |
| Modality | Other / unclassified | “Coxsackievirus A21, a naturally occurring enterovirus” NCT00235482 ↗ |
| Route | Other | “a single intratumoural injection of the virus” NCT00235482 ↗ |
| Target | ICAM1 | “ICAM-1-targeted immunotherapeutic-coxsackievirus A21” PMID 31273010 ↗ Jul 2019 |